1型糖尿病免疫治疗试验长期随访显示副作用谱良性
本研究对14项1型糖尿病免疫治疗随机对照试验的参与者进行长期随访,观察至原试验结束后中位1.78年(最长18年),比较活性治疗与安慰剂组自我报告的健康结局。结果显示两组在中重度低血糖、住院、严重感染(含COVID-19)、新过敏反应、自身免疫病及癌症发生率上均无差异(P>0.05)。
要点
- 免疫治疗组与安慰剂组自我报告健康结局无显著差异。
- 中位随访1.78年,部分参与者长达18年。
- 需持续对免疫治疗试验参与者进行长期随访。
核心结论
- 在1型糖尿病免疫治疗试验参与者中,未观察到活性免疫治疗与安慰剂在自我报告健康结局上的差异。
研究设计与样本
- 来自14项随机对照试验的参与者(47%)加入长期随访研究,98%回答了至少一个健康相关结局问题。
主要发现
- 参与者原试验完成后中位随访1.78年(四分位距0.89-4.04),部分长达18年。
- 自我报告健康结局包括中重度低血糖事件、住院、严重感染(含COVID-19)、新过敏反应、自身免疫病及癌症发生率,活性治疗与安慰剂组间无差异(每问题n=209-473,所有P>0.05)。
临床怎么用
- 提示1型糖尿病免疫治疗试验中活性治疗未增加长期自我报告不良健康结局,支持继续开展长期随访。
局限性
- 健康结局为自我报告,可能存在报告偏倚;随访时间不等,部分结局应答数有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Long-term side effect surveillance after immunotherapy clinical trial participation in individuals with or at risk of type 1 diabetes is needed. RESEARCH DESIGN AND METHODS: Participants from 14 randomized controlled trials (47%) joined the Long-term Investigative Follow-up in Type 1 Diabetes TrialNet or Immune Tolerance Network Type 1 Diabetes Extension Study, and 98% answered at least one health-related outcomes question. RESULTS: Participants were observed for a median of 1.78 (interquartile range 0.89-4.04) years after original trial completion and, in some, up to 18 years. There were no differences in the frequency of self-reported health outcomes, including moderate to severe hypoglycemia events, hospitalizations, serious infections (including COVID-19 infection), new allergic reactions, autoimmune disease, and cancer incidence, between those receiving active and placebo therapy (n = 209-473 responses per question; P > 0.05 for all). CONCLUSIONS: We observed no differences in self-reported health outcomes between those who received active immunotherapy versus placebo. Continued long-term follow-up of immunotherapy trial participants is essential.
引用
- Jacobsen LM, Cuthbertson D, Felton J, et al. Extended Follow-up of Type 1 Diabetes Immunotherapy Trial Participants Suggests Benign Side Effect Profile. Diabetes Care. 2026. PMID: 42283716. doi:10.2337/dc26-0632
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。